The information on this site is intended for adult residents
of the United States.

Close the layer

You Are Now Leaving

By following this link, you are now leaving www.TRUVADApreprems.com.
These sites are not controlled by Gilead Sciences, Inc. Gilead Sciences, Inc. is not responsible for their content or your use of them.

Close the layer

TRUVADA for a PrEP indication should be used only:

  • A. As part of a comprehensive HIV-1 prevention strategy that includes other preventive measures, since TRUVADA is not always effective in preventing the acquisition of HIV-1 infection
  • B. In individuals who have been counseled to strictly adhere to their TRUVADA daily dosing schedule, since the effectiveness of TRUVADA in reducing the risk of acquiring HIV-1 infection is strongly correlated with adherence and measurable drug levels
  • C. In individuals who have a confirmed negative HIV-1 test prior to initiating and routinely while taking TRUVADA for a PrEP indication
  • D. All of the above

Which of the following statements is false?

  • A. TRUVADA should be used for a PrEP indication only in individuals confirmed to be HIV-1 negative
  • B. TRUVADA has been found to be safe and effective for pre-exposure prophylaxis to reduce the risk of acquiring HIV-1 infection through injection drug use
  • C. Women taking TRUVADA for a PrEP indication should not breastfeed their babies
  • D. TRUVADA for a PrEP indication is not always effective in preventing HIV-1 infection

Which of the following items are not included on the Checklist for Prescribers for initiating TRUVADA for a PrEP indication?

  • A. Perform HBV screening test
  • B. Perform testing for TB
  • C. Confirm negative HIV-1 status of the individual
  • D. Confirm creatinine clearance is ≥60 mL/min

Hepatic function should be monitored closely in:

  • A. HBV-infected individuals who discontinue TRUVADA
  • B. All people taking TRUVADA
  • C. All people who discontinue TRUVADA
  • D. None of the above

In clinical trials evaluating TRUVADA for a PrEP indication, which of the following adverse reactions was not common?

  • A. Abdominal pain
  • B. Headache
  • C. Dizziness
  • D. Decreased weight

TRUVADA for a PrEP indication is indicated only for:

  • A. Men who are at high risk for sexually acquired HIV-1 infection
  • B. Adults who are at high risk of acquiring HIV-1 infection by any means
  • C. Adults who are at high risk of acquiring HIV-1 infection through injection drug use
  • D. Adults who are at high risk for sexually acquired HIV-1 infection

The Agreement Form for Initiating TRUVADA for Pre-exposure Prophylaxis (PrEP) provides which of the following information:

  • A. A list of activities that put individuals at risk for sexually acquired HIV-1 infection
  • B. A confirmation that the prescriber has discussed the risks and benefits of using TRUVADA for a PrEP indication with the uninfected individual
  • C. A signature from the individual asserting that the prescriber has explained the risks and benefits of taking TRUVADA for a PrEP indication, including the need for adherence and a comprehensive prevention strategy, which includes safer sex practices
  • D. All of the above

To help Gilead and the FDA understand who has viewed this training, please tell us the following


Report completion of training for TRUVADA for a PrEP indication

Participate in a Knowledge, Attitude, and Behavior (KAB) survey to assess the use and understanding of TRUVADA for PrEP

Incorrect. Please try again.

Try Again

Correct

Next